Clinical Trial Update: A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating pyrotinib plus capecitabine for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2 Positive Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN